Oncoarendi Therapeutics SA logo

OAT - Oncoarendi Therapeutics SA Share Price

PLN10 0.0  0.0%

Last Trade - 4:35pm

Sector
Healthcare
Size
Micro Cap
Market Cap £28.2m
Enterprise Value £22.8m
Revenue £0.356k
Position in Universe 309th / 761
Bullish
Bearish
Unlock OAT Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Oncoarendi Therapeutics SA revenues decreased from PLN1K to PLN0K. Net loss decreased 30% to PLN894K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Motivation Programme Expense decrease from PLN350K (expense) to PLN0K, Labor & Related Expenses in SGA decrease of 14% to PLN436K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

OAT Revenue Unlock OAT Revenue

Net Income

OAT Net Income Unlock OAT Revenue

Normalised EPS

OAT Normalised EPS Unlock OAT Revenue

PE Ratio Range

OAT PE Ratio Range Unlock OAT Revenue

Dividend Yield Range

OAT Dividend Yield Range Unlock OAT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
OAT EPS Forecasts Unlock OAT Revenue
Profile Summary

OncoArendi Therapeutics SA (OAT) is a Poland-based biopharmaceutical company dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The Companys business model is strictly focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations with the key opinion leaders in specific disease areas.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated January 4, 2017
Public Since April 19, 2018
No. of Shareholders: n/a
No. of Employees: 83
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Warsaw Stock Exchange
Shares in Issue 13,670,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
OAT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for OAT
Upcoming Events for OAT
Thursday 18th June, 2020 Estimate
Oncoarendi Therapeutics SA Annual Shareholders Meeting
Frequently Asked Questions for Oncoarendi Therapeutics SA
What is the Oncoarendi Therapeutics SA share price?

As of 4:35pm, shares in Oncoarendi Therapeutics SA are trading at PLN10, giving the company a market capitalisation of £28.2m. This share price information is delayed by 15 minutes.

How has the Oncoarendi Therapeutics SA share price performed this year?

Shares in Oncoarendi Therapeutics SA are currently trading at PLN10 and the price has moved by -26.09% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Oncoarendi Therapeutics SA price has moved by -22.44% over the past year.

What are the analyst and broker recommendations for Oncoarendi Therapeutics SA?

Of the analysts with advisory recommendations for Oncoarendi Therapeutics SA, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Oncoarendi Therapeutics SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Oncoarendi Therapeutics SA next release its financial results?

Oncoarendi Therapeutics SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Oncoarendi Therapeutics SA dividend yield?

Oncoarendi Therapeutics SA does not currently pay a dividend.

Does Oncoarendi Therapeutics SA pay a dividend?

Oncoarendi Therapeutics SA does not currently pay a dividend.

When does Oncoarendi Therapeutics SA next pay dividends?

Oncoarendi Therapeutics SA does not currently pay a dividend.

How do I buy Oncoarendi Therapeutics SA shares?

To buy shares in Oncoarendi Therapeutics SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Oncoarendi Therapeutics SA?

Shares in Oncoarendi Therapeutics SA are currently trading at PLN10, giving the company a market capitalisation of £28.2m.

Where are Oncoarendi Therapeutics SA shares listed? Where are Oncoarendi Therapeutics SA shares listed?

Here are the trading details for Oncoarendi Therapeutics SA:

Country of listing: Poland
Exchange: WSE
Ticker Symbol: OAT
What kind of share is Oncoarendi Therapeutics SA?

Based on an overall assessment of its quality, value and momentum, Oncoarendi Therapeutics SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Oncoarendi Therapeutics SA share price forecast 2020?

Shares in Oncoarendi Therapeutics SA are currently priced at PLN10. At that level they are trading at 0.171% discount to the analyst consensus target price of 0.00.

Analysts covering Oncoarendi Therapeutics SA currently have a consensus Earnings Per Share (EPS) forecast of -0.05 for the next financial year.

How can I tell whether the Oncoarendi Therapeutics SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncoarendi Therapeutics SA. Over the past six months, the relative strength of its shares against the market has been 15.51%. At the current price of PLN10, shares in Oncoarendi Therapeutics SA are trading at -8.49% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Oncoarendi Therapeutics SA PE Ratio?

We were not able to find PE ratio data for Oncoarendi Therapeutics SA.

Who are the key directors of Oncoarendi Therapeutics SA?

Oncoarendi Therapeutics SA's management team is headed by:

Krzysztof Laskowski - CSU
Marcin Szumowski - CMG
Adam Golebiowski - VPR
Slawomir Broniarek - FID
Jacek Olczak - VPR
Karolina Dzwonek - VPR
Mariusz Gromek - VSU
Marta Borkowska - COO
Nicolas Beuzen - VBD
Grzegorz Mironski - SUB
Henryk Gruza - SUB
Pawel Dobrzanski - SDR
Piotr Zolkiewicz - SUB
Who are the major shareholders of Oncoarendi Therapeutics SA?

Here are the top five shareholders of Oncoarendi Therapeutics SA based on the size of their shareholding:

Ipopema Towarzystwo Funduszy Inwestycyjnych S.A. Investment Advisor
Percentage owned: 30.25% (4.14m shares)
Szumowski (Marcin Jan Ph.D.) Individual Investor
Percentage owned: 8.88% (1.21m shares)
Golab (Jakub) Individual Investor
Percentage owned: 5.97% (816k shares)
Golebiowski (Adam Ph.D.) Individual Investor
Percentage owned: 5.84% (799k shares)
New Europe Ventures, L.L.C. Venture Capital
Percentage owned: 5.59% (765k shares)
Similar to OAT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.